Lei Jianping on December 23Avian Hospital Management Group *** referred to as "Aviave") recently submitted a prospectus to be listed on the Hong Kong Stock Exchange.
Revenue in the first half of the year was 2300 million
Aviaves Hospital Group was founded in 2006 under the guidance of Professor Zhang Lizhu, the "Mother of IVF in China". "Aviaf" is the transliteration of IVF (Invitro Fertilization), IVF is the abbreviation of in vitro fertilization technology, which is often referred to as "test tube baby".
Focusing on the field of human assisted reproduction for nearly 20 years, AVIE Group is a large-scale international investment institution featuring human assisted reproductive technology (IVF), and its hospital services cover reproductive **, TCM infertility, difficult IVF consultation, habitual abortion, pregnancy preparation guidance center, child development and other disciplines.
Avieve Group owns a number of medical entities such as Zhanjiang Jiuhe Hospital, Jieyang Avi Hospital, Tianjin Avi Hospital, Kunming Avi Hospital, etc., covering 15 provinces, autonomous regions and cities across the country, including Beijing, Tianjin, Hebei, Shandong, Yunnan, Guizhou, Guangdong, Guangxi, and Hainan.
In terms of international cooperation, Avieve Group has maintained close exchanges with institutions such as Stanford University Reproductive Center in the United States, Kato Women's Hospital in Japan, IVF Center in Sydney, Australia, and Avreve International Center for Reproductive Medicine in Taiwan. It has successively introduced advanced diagnosis and treatment technologies such as vitrification, microstimulation program, natural cycle**, ovarian in vitro activation (IVA), endometrial receptivity analysis and testing (ERA), electrophysiology appropriate technology, embryo jet lag culture, etc., to ensure the steady improvement of clinical pregnancy rate.
According to the prospectus, Aviaf's revenue in 2020, 2021, and 2022 will be 36.9 billion yuan, 4200 million yuan, 40.7 billion yuan;The profit during the period was 45.96 million yuan, 94.56 million yuan and 64.52 million yuan respectively.
Aviaf's revenue for the first half of 2023 is 2300 million, compared with revenue of 1 in the same period last year7.7 billion yuan;The profit for the period was 33.88 million yuan, compared with 13.65 million yuan in the same period last year.
As of June 30, 2023, Aviave had cash and cash equivalents of 10.8 billion yuan. Ren Jizhong controls 92% of the shares
The executive directors of Avieve are Ren Jizhong, Ms. Huang Yaqin and Ms. Zhang LianyueThe non-executive directors are Ms. Zhang Xiaowen, and the independent non-executive directors are Ms. Chen Ling, Ms. Zhao Guiying and Ms. Sun Wei. 
Before the IPO, Nanshan Laterite held 46%, and Shenzhen Capital holds 192%, Futian Red Clay holds 167%, Ren Jizhong holds 9181%。
The last assisted reproduction company listed on the Hong Kong stock market was called Jinxin Reproduction, which was listed on the Hong Kong Stock Exchange in 2019 with an issue price of 8HK$54, with a net proceeds of 28HK$0.8 billion.
Once Aviaf is listed on the Hong Kong Stock Exchange, it also means that there will be one more assisted reproduction company in the Hong Kong stock market.
Lei Di was founded by ** Lei Jianping, if ** please in**.